Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies

Phase 1/2 Completed 111 enrolled Novartis Pharmaceuticals XOMA (US) LLC · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is to evaluate the highest tolerated dose, safety and activity of HCD122 in adults with non-Hodgkin's or Hodgkin's lymphoma who have received at least two prior therapies.

Timeline

Start: 2008-03
Primary completion: 2013-02
Completion: 2013-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lucatumumab	Monoclonal antibody	—	Intravenous

Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies

Summary

Timeline

Drugs

Indications